Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States
article
OA: gold
CC0
AI-generated summary
Women with endometriosis in the US prioritize pain relief, reduced out-of-pocket costs, and rapid, safe treatment onset when choosing GnRH agonists/antagonists.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other features.
OBJECTIVES: This study quantified the importance that women with endometriosis in the United States (US) placed on pain and non-pain features that differ among these medications.
DESIGN: English-speaking, 18 to 50 years (premenopausal) US women with healthcare coverage for the past 3 years, who self-reported a laparoscopy-confirmed endometriosis diagnosis, were recruited via healthcare research panels to complete a cross-sectional survey.
METHODS: A discrete choice experiment (DCE) with a surgery opt-out option assessed preferences for eight GnRH agonist/antagonist attributes (reducing different types of pain, treatment administration, impact on daily activities, etc.). Best-worst scaling (BWS) assessed preferences for 11 non-pain medication attributes (dosage flexibility, short treatment onset, reversible side effects, etc.). Relative importance (RI) was estimated for each attribute.
RESULTS: Overall, 300 women were included (mean age 33.0 years; 76.7% White). Across DCE choice tasks, GnRH agonist/antagonist was chosen over surgery 46.7% of the time. Non-menstrual pelvic pain relief (RI = 23.1%), reducing monthly OOP cost (RI = 22.1%), and relief of dyspareunia (RI = 21.4%) and dysmenorrhea (RI = 12.9%) were most important for GnRH treatment choice. Among non-pain attributes in the BWS, short onset of treatment effect (RI = 13.1%), long-term safety (RI = 12.9%), and reducing fatigue (RI = 11.2%) were most important to women when choosing a pharmacologic endometriosis treatment.
CONCLUSION: Relieving the three types of endometriosis pain and reducing cost are the most important considerations for women when selecting GnRH agonist/antagonist treatment. Women with endometriosis strongly prefer a medication that can be safely taken for longer periods of time, takes effect within a few menstrual cycles, and can reduce endometriosis-related fatigue. Findings can inform discussions between patients and healthcare providers to better align endometriosis treatment decision-making with patients' individual needs and preferences.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (35)
- Characteristics of Women with Endometriosis from the USA and Puerto Rico via openalex
- Clinical diagnosis of endometriosis: a call to action via openalex
- Demographics and Hospital Outcomes in American Women With Endometriosis and Psychiatric Comorbidities via openalex
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review via openalex
- Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment? via openalex
- Influence of race/ethnicity on prevalence and presentation of endometriosis: a systematic review and meta‐analysis via openalex
- Introduction via openalex
- Is Endometriosis More Common and More Severe Than It Was 30 Years Ago? via openalex
- Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review via openalex
- Patient Preferences for Endometriosis Pain Treatments in the United States via openalex
- Patients’ Preferences Related to Treatments for Endometriosis-Related Pain: Results of a Discrete Choice Experiment in the UK via openalex
- Recognising, understanding and managing endometriosis via openalex
- Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of the literature via openalex
- Repetitive surgery for recurrent symptomatic endometriosis: What to do? via openalex
- The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study via openalex
- The Clinical Anatomy of Endometriosis: A Review via openalex
- The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home via openalex
- Women with endometriosis in the United States: National Survey of Family Growth, 2011–2019 via openalex
- W2130649333 via openalex
- W3111516481 via openalex
- W1968014510 via openalex
- W3165510799 via openalex
- W2121619367 via openalex
- W3176859668 via openalex
- W4205756642 via openalex
- W4214754424 via openalex
- W4225724637 via openalex
- W1602006543 via openalex
- W4319047117 via openalex
- W4319311385 via openalex
- W4402650683 via openalex
- W2367707061 via openalex
- W2059796825 via openalex
- W2048533792 via openalex
- W2222641375 via openalex
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pmc
- last seen: 2026-05-13T20:22:03.195721+00:00
- pubmed
- last seen: 2026-06-12T06:10:14.901819+00:00
License: CC0
· commercial use OK